Cheryl Coons
Psychiatric/Mental Health · Lenexa, KSNPI 1770108680
Payments from drug & device makers
Across 196 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$772
- Vanda Pharmaceuticals Inc.$403
- Supernus Pharmaceuticals, Inc.$359
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$315
- Otsuka America Pharmaceutical, Inc.$271
- Axsome Therapeutics, Inc.$266
- plus $816 from 13 others
What the payments were for
- Food & beverage$3,202100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 54 | $772 |
| Vanda Pharmaceuticals Inc. | 22 | $403 |
| Supernus Pharmaceuticals, Inc. | 28 | $359 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $315 |
| Otsuka America Pharmaceutical, Inc. | 16 | $271 |
| Axsome Therapeutics, Inc. | 17 | $266 |
| Teva Pharmaceuticals USA, Inc. | 13 | $254 |
| Lundbeck LLC | 5 | $105 |
| E.r. Squibb & Sons, L.L.C. | 4 | $82 |
| Bausch Health US, LLC | 3 | $59 |
| Noven Therapeutics, LLC | 3 | $58 |
| Johnson & Johnson | 3 | $55 |
| Neurocrine Biosciences, Inc. | 2 | $52 |
| Almatica Pharma LLC | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Alkermes, Inc. | 1 | $30 |
| OWP Pharmaceuticals, Inc. | 1 | $18 |
| Neos Therapeutics, LP | 1 | $16 |
| Tris Pharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$102
How this compares
$3,202 in reported general payments places this provider in the 80th percentile of 404 psychiatric/mental health providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 11 | $958 |
| Duloxetine Hcl | 15 | $478 |
| Prazosin Hcl | 15 | $419 |
| Buspirone Hcl | 23 | $302 |
| Sertraline Hcl | 28 | $192 |
| Quetiapine Fumarate | 13 | $116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $39 | $19228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 404 psychiatric/mental health providers in Kansas.
Other psychiatric/mental health in Lenexa
- Appoloniah KimaniLenexa$10K
- Hilder NjorogeLenexa$9K
- Valerie JansenLenexa$8K
- Francis ChegeLenexa$6K
- Eric ThomasonPittsburg$333K
- Belinda BagbyHutchinson$39K
- Hayley KnappWichita$31K
- Jennifer KubinBaldwin City$26K
- Uyen DinhPittsburg$20K
- Louise MuhoziKansas City$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.